Cialis vs Sildenafil (Generic): Head-to-Head Efficacy Compared

How Tadalafil and Sildenafil Work

Both drugs block phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. When PDE5 is inhibited, cyclic GMP accumulates, smooth muscle relaxes, and blood flow into the corpus cavernosum increases enough to produce an erection in response to sexual stimulation. Neither drug creates an erection on its own; arousal is required.

The mechanism is identical. The pharmacokinetics are not.

Half-Life: The Central Difference

Tadalafil has a plasma half-life of approximately 17.5 hours, compared with 3 to 5 hours for sildenafil. That longer half-life is why tadalafil remains clinically active for up to 36 hours after a single dose, a property that earned it the informal nickname "the weekend pill." Sildenafil's shorter half-life means the window for intercourse is narrower, typically 4 to 6 hours after dosing [1].

Mechanism of Selectivity

Both drugs are selective for PDE5 over other PDE isoforms, though sildenafil has somewhat greater affinity for PDE6 (found in retinal photoreceptors), which explains the transient blue-tinge visual disturbance reported by roughly 3% of sildenafil users. Tadalafil has greater affinity for PDE11, an isoform found in skeletal muscle and testes, which may explain the myalgia and back pain that are more common with tadalafil than with sildenafil [2].

Approved Doses and Dosing Schedules

Getting the dose right matters as much as choosing the drug. Both agents have narrow therapeutic windows where efficacy is high and tolerability is acceptable.

Tadalafil Dosing

The FDA-approved as-needed doses for tadalafil are 5 mg, 10 mg, and 20 mg, taken at least 30 minutes before sexual activity. The 10 mg dose is the standard starting point. For men who prefer predictable readiness or who have benign prostatic hyperplasia (BPH), tadalafil 5 mg once daily is FDA-approved for both indications simultaneously, no on-demand timing needed [3].

Sildenafil Dosing

Generic sildenafil for ED is available as 25 mg, 50 mg, and 100 mg tablets. The 50 mg as-needed dose is the standard starting point for most men; clinicians may titrate up to 100 mg or down to 25 mg based on response and tolerability. Sildenafil 20 mg tablets (branded as Revatio for pulmonary arterial hypertension) are widely available generically at substantially lower cost, and some prescribers use three 20 mg tablets (60 mg total) as an off-label ED dose, though the 50 mg and 100 mg formulations remain the approved ED doses [4].

Why Dose Flexibility Matters Clinically

A man with diabetes and ED who also has BPH gains a practical advantage from tadalafil 5 mg daily: one pill addresses two conditions. A younger man who has occasional intercourse and prefers spontaneity within the same evening may find sildenafil's 4-to-6-hour window entirely adequate.

Head-to-Head Efficacy: What the Trials Actually Show

No single large-scale randomized controlled trial has directly compared tadalafil and sildenafil at their respective FDA-approved ED doses with identical methodology. The evidence base is composed of individual placebo-controlled trials and a smaller number of direct comparison studies.

Individual Key Trials

Goldstein et al. Published the landmark sildenafil trial in the New England England Journal of Medicine in 1998 (N=532). Sildenafil-treated men reported successful intercourse on 69% of attempts versus 22% in the placebo group (P<0.001). The International Index of Erectile Function (IIEF) erectile function domain score improved by a mean of 7.0 points over placebo [1].

Brock et al. (J Urol 2002) assessed tadalafil 10 mg and 20 mg over 12 weeks in men with ED of broad etiology. Tadalafil 20 mg produced successful intercourse on approximately 75% of attempts versus 32% for placebo. The IIEF erectile function domain improved by 6.5 to 7.3 points over placebo, figures broadly similar to sildenafil's effect size [2].

Cross-Trial Comparison Table

| Parameter | Sildenafil 50 to 100 mg (as-needed) | Tadalafil 10 to 20 mg (as-needed) | |---|---|---| | Successful intercourse attempts vs placebo | +47 percentage points (Goldstein 1998) | +43 percentage points (Brock 2002) | | IIEF-EF domain improvement over placebo | ~7.0 points | 6.5 to 7.3 points | | Onset | 30 to 60 min | 30 to 60 min | | Duration of action | 4 to 6 hours | Up to 36 hours | | Food effect | High-fat meal reduces Cmax ~29% | Clinically negligible | | Back/muscle pain | Rare | 3 to 7% of users | | Visual disturbances | ~3% (PDE6 affinity) | Rare |

Cross-trial comparisons carry inherent limitations: different populations, different placebo rates, and different epochs. Direct comparison data is discussed below.

Direct Head-to-Head Studies

A 2011 crossover trial published in the Journal of Sexual Medicine (N=150) allowed men to self-administer both sildenafil 50 mg and tadalafil 10 mg on separate occasions over 12 weeks, then state a preference. Approximately 67% of men preferred tadalafil, citing the longer window of opportunity [5]. Efficacy on IIEF scores was not statistically different between the two drugs.

A 2005 meta-analysis by Tsertsvadze et al. Synthesized 82 trials covering all three major PDE5 inhibitors. The authors concluded that all approved PDE5 inhibitors showed "similar clinical efficacy," with no significant difference in IIEF improvement between tadalafil and sildenafil when head-to-head data were pooled [6].

The HealthRX clinical team uses a four-factor triage framework when recommending one agent over the other: (1) intercourse frequency, defined as whether the patient has sex more or fewer than three times per week; (2) the presence of BPH symptoms scored on the International Prostate Symptom Score; (3) dietary habits, specifically whether the patient routinely eats high-fat meals before intercourse; and (4) whether the patient has had prior sildenafil-related visual symptoms. Men who score "frequent sex plus BPH" almost always benefit from tadalafil 5 mg daily. Men who score "infrequent sex, no BPH, no fat-meal conflict" are good candidates for either drug selected by cost.

Efficacy in Special Populations

ED is rarely an isolated diagnosis. Most men presenting to a telehealth platform have at least one comorbidity that modifies both drug selection and expected efficacy.

Diabetes-Related ED

Men with diabetes have more severe neurovascular ED and historically lower response rates to PDE5 inhibitors than the general population. In a pooled analysis of tadalafil trials, men with diabetes showed a mean IIEF improvement of 4.9 points over placebo, lower than the 7-point improvement seen in the overall population but still clinically meaningful (a 4-point change is the minimum clinically important difference on the IIEF-EF domain) [7].

Sildenafil shows similar patterns: a Cochrane systematic review confirmed that sildenafil improved erectile function in men with diabetes compared with placebo, though absolute response rates were lower than in non-diabetic men [8]. No reliable head-to-head trial in a diabetes-only cohort has been completed at sufficient power to declare one drug superior.

Post-Prostatectomy ED

Radical prostatectomy causes cavernous nerve damage that can render PDE5 inhibitors less effective. Tadalafil 5 mg once daily has been studied as penile rehabilitation therapy in this setting: the REACTT trial (N=139) showed that daily tadalafil 5 mg did not improve the rate of return of unassisted natural erections at 9 months compared with on-demand tadalafil or placebo, though men in the daily-dosing arm had better IIEF scores while on treatment [9]. Sildenafil in the post-prostatectomy setting shows comparable response rates in observational data.

Cardiovascular Comorbidity

Both drugs lower systolic blood pressure by approximately 5 to 8 mmHg through PDE5 inhibition in vascular smooth muscle. The absolute contraindication is co-administration with any nitrate (nitroglycerin, isosorbide mononitrate, amyl nitrite). The Princeton Consensus (Third) guidelines classify most men with stable cardiovascular disease as low-risk and appropriate for PDE5 inhibitor use after physician evaluation [10].

Tadalafil's longer half-life means the nitrate window is broader: a man who takes tadalafil must wait at least 48 hours before any nitrate can be administered safely. With sildenafil, the wait is at least 24 hours.

Side-Effect Profile and Tolerability

Shared Side Effects

Headache (10 to 16% incidence), facial flushing (5 to 12%), and nasal congestion (3 to 8%) appear at similar rates with both drugs in randomized trials. These are direct PDE5 effects in vascular beds outside the penis and are dose-dependent.

Dyspepsia (acid reflux-like symptoms) occurs in 4 to 10% of sildenafil users and roughly 3 to 5% of tadalafil users, a modest but real difference attributed to tadalafil's additional inhibition of PDE11 in the lower esophageal sphincter region.

Drug-Specific Side Effects

Sildenafil's affinity for retinal PDE6 produces transient blue-green tinge, blurred vision, or increased light sensitivity in approximately 3% of users at the 100 mg dose. This effect is dose-dependent and not reported with tadalafil at therapeutic doses.

Myalgia and lower back pain occur in 3 to 7% of tadalafil users, thought to be related to PDE11 activity in skeletal muscle. These effects are far less common with sildenafil.

Rare but Serious Events

Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare but documented association with all PDE5 inhibitors. The FDA added a labeling warning in 2005. The absolute risk appears very low, but men with a history of NAION or optic nerve disorders should avoid this drug class [11].

Sudden hearing loss has been reported in post-marketing surveillance with both agents. This event is rare and causality is not firmly established, but clinicians should counsel patients to discontinue the drug and seek immediate evaluation if sudden hearing change occurs.

Food, Alcohol, and Timing Interactions

The High-Fat Meal Problem with Sildenafil

Sildenafil's absorption is significantly slowed and reduced by a high-fat meal. A standard pharmacokinetic study found that a high-fat meal delayed the median time to peak plasma concentration (Tmax) from 60 minutes to 120 minutes and reduced peak plasma concentration (Cmax) by 29% [12]. For a man eating a steak dinner before date night, this is clinically relevant: the drug may not reach effective plasma levels when he expects it to.

Tadalafil shows no meaningful food interaction. Rate and extent of absorption are unaffected by food content or timing, making it the more forgiving choice for men who cannot predict meal composition.

Alcohol

Moderate alcohol (up to 3 standard drinks) does not substantially change the pharmacokinetics of either drug. Both drugs do potentiate the vasodilatory effect of alcohol, so the combination may increase the likelihood of symptomatic hypotension, dizziness, or orthostatic symptoms. The prescribing information for both drugs cautions against excessive alcohol use.

Cost Comparison: Generic Sildenafil vs Generic Tadalafil

Both drugs are available as low-cost generics in the United States following patent expiration (sildenafil generic launched in December 2017; tadalafil generic launched in 2018). As of early 2025, cash prices at major pharmacies are broadly comparable, though sildenafil 20 mg tablets (the Revatio-dose tablets) often carry the lowest per-dose cost when three are used together to approximate a 60 mg ED dose.

With a GoodRx-type discount or through telehealth subscription models, either drug can often be obtained for $1 to $3 per dose. Daily tadalafil 5 mg is typically $0.50 to $1.00 per day in generic form, making it cost-competitive with sildenafil even on a per-day basis.

Insurance coverage varies. Medicare Part D plans generally cover generic sildenafil and tadalafil when prescribed for ED, though prior authorization may be required.

Switching Between Tadalafil and Sildenafil

Switching is both safe and common. Because there is no drug accumulation risk from discontinuing one PDE5 inhibitor and starting another (no pharmacological cross-tolerance has been identified), a clinician can simply stop one and start the other.

The clinical indication to switch is usually one of three scenarios: (1) the current drug is effective but produces intolerable side effects (e.g., visual symptoms on sildenafil warrant a switch to tadalafil); (2) the current drug is not producing sufficient erections at the maximum tolerated dose, prompting a trial of the alternate agent; or (3) lifestyle changes make the other drug's pharmacokinetic profile more suitable.

A 2010 study in the International Journal of Impotence Research found that approximately 40% of men who switched from sildenafil to tadalafil after inadequate response went on to have successful intercourse with tadalafil, suggesting non-overlapping partial responder populations [13]. Trying the alternate drug before labeling a patient "PDE5 inhibitor non-responder" is consistent with the 2018 American Urological Association (AUA) guideline on ED, which states: "Clinicians should recommend the use of PDE5 inhibitors to men with ED who desire treatment" and notes that adequate trial includes using the drug at maximum tolerated dose on at least four separate occasions with proper stimulation [14].

Tadalafil for BPH: A Distinct Advantage

Tadalafil 5 mg once daily is the only PDE5 inhibitor with FDA approval for lower urinary tract symptoms (LUTS) secondary to BPH, with or without concomitant ED. A pooled analysis of four randomized controlled trials (N=1,499) showed that tadalafil 5 mg reduced the International Prostate Symptom Score (IPSS) by a mean of 4.9 points over placebo at 12 weeks, comparable to the 5.2-point improvement seen with alpha-blocker monotherapy [3].

This dual benefit means a man in his 50s or 60s who has both ED and urinary hesitancy, frequency, or incomplete emptying may replace two medications (an alpha-blocker and a PRN PDE5 inhibitor) with a single daily tadalafil 5 mg tablet. Sildenafil has no approved BPH indication and no substantial trial data in this setting.

Who Should Choose Tadalafil

Choose tadalafil when:

• You want spontaneity over a 24-to-36-hour window rather than a fixed 4-to-6-hour window
• You have BPH symptoms concurrent with ED
• You routinely eat high-fat meals before potential sexual activity
• You are having sex three or more times per week (daily dosing may be more economical than per-use dosing)
• You had transient visual disturbances on sildenafil

Who Should Choose Sildenafil

Choose sildenafil when:

• You have sex infrequently and a 4-to-6-hour window is sufficient
• You prioritize the lowest possible per-dose cost
• You had significant myalgia or back pain on tadalafil
• Your prescriber is familiar with titrating sildenafil 20 mg tablets for cost-reduction off-label use
• You have no BPH symptoms and no food-timing conflicts